research Novel Investigational Drugs for Alopecia Areata and Future Perspectives
JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
Search
for
Sort by
Research
570-600 / 1000+ results 
research Low-Dose Oral Minoxidil Improves Hair Length and Global Hair Density in Short Anagen Syndrome
Low-dose minoxidil helps hair grow longer and thicker in people with short anagen syndrome.
research Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
research Treatment of Moderate-to-Severe Alopecia Areata in Patients Over the Age of 65 With Baricitinib
Baricitinib helps treat severe hair loss in people over 65.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Clinical Benefits of Baricitinib Therapy for Severe Alopecia Areata
Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.
research Long-Term Efficacy of Baricitinib in the Treatment of Alopecia Areata: Results at Week 104 from the BRAVE-AA1 and BRAVE-AA2 Studies
Baricitinib effectively treats severe alopecia for up to 104 weeks.
research Evaluating 5 Alpha Reductase Inhibitors for the Treatment of Male Androgenic Alopecia
Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Incidence and Prevalence of Alopecia Areata in the Australian Primary Care Setting: A Retrospective Analysis of Electronic Health Record Data
The analysis found that alopecia areata, a hair loss condition, is not very common in Australia, affecting about 0.13% of people, with new cases most often seen in males aged 19 to 34 years.
research Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response
Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
research An Evaluation of the Available Pharmacotherapy for the Treatment of Hirsutism
Birth control pills and antiandrogens are the most effective medicines for excessive body hair in women, but combining them with other treatments and psychological support is best.
research Treatment of Moderate-to-Severe Alopecia Areata in Adolescents With Baricitinib: A Retrospective Review of 29 Patients
Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
research Decision Letter: Involvement of ILC1-Like Innate Lymphocytes in Human Autoimmunity, Lessons from Alopecia Areata
ILC1-like cells may contribute to hair loss in alopecia areata and could be new treatment targets.
research Signposts to the Promised Land in Alopecia Areata
Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
research Vitamin D Status in Patients with Frontal Fibrosing Alopecia: A Retrospective Study
Women with frontal fibrosing alopecia have similar vitamin D levels to those with other hair loss types, suggesting vitamin D is not a key factor in this condition.
research Hair Loss in an 11-Year-Old: Successful Treatment of Alopecia Universalis with Baricitinib and Minoxidil
An 11-year-old girl with severe hair loss was successfully treated with a new combination therapy.
research Minoxidil: What It Is and How It Works
Minoxidil helps hair growth.
research Alopecia Areata Mimicking Frontal Fibrosing Alopecia
A woman's hair loss was initially misdiagnosed as scarring hair loss but was actually a treatable autoimmune hair loss.
research Telogen Effluvium: A Common Form of Hair Loss
Telogen Effluvium is a common, usually reversible hair loss condition, often improved by removing the trigger and possibly treated with various products, though their effectiveness is uncertain.
research Measuring the Impact of Alopecia Areata
research Alpha-1 Adrenergic Receptor Agonist Induced Piloerection Protects Against the Development of Traction Alopecia
Phenylephrine may help prevent hair loss from pulling on the hair roots.
research Alopecia Areata: An Overview of Treatments and Efficacy
No treatment alters the natural progression of alopecia areata, and effectiveness varies, with some possibly working better in children.
research What Amount of Hair Do Women Want?
Women generally want more hair volume, which becomes a concern around menopause due to hair loss.
research Letters to the Editors: Response to Jimenez/Poblet
The document's conclusion cannot be determined from the provided text.
research Trichorrhexis Nodosa Improving With Oral Minoxidil: A Case Report
Oral minoxidil may help improve fragile hair.
research Regrowth of Hair in Congenital Triangular Alopecia Induced by Sublingual Minoxidil
Sublingual minoxidil helped regrow hair in a person with congenital triangular alopecia.
research Systemic Minoxidil for Hair Disorders in Pediatric Patients: A Safety and Tolerability Review
Low-dose oral and sublingual minoxidil seem safe for children with hair disorders.
research Reply to: Comment on Bicalutamide Improves Minoxidil-Induced Hypertrichosis in Female Pattern Hair Loss: A Retrospective Review of 35 Patients
research Faculty Opinions Recommendation of Topical Finasteride for the Treatment of Male Androgenetic Alopecia and Female Pattern Hair Loss: A Review of the Current Literature
Topical finasteride is promising for hair loss with minimal side effects but needs more research and approval.